Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Objective: Maturity onset diabetes of the young (MODY) occurs due to mutations in genes involved in pancreatic beta cell function and insulin secretion, has heterogeneous clinical and laboratory features, and account for 1-5% of all diabetes cases. The prevalence and distribution of MODY subtypes vary between countries. The aim of this study was to evaluate the clinical and laboratory characteristics, mutation distribution, and phenotype-genotype relationship in a large case series of pediatric Turkish patients genetically diagnosed with MODY.

Methods: MODY cases from 14 different pediatric endocrinology departments were included. Diagnosis, treatment, follow-up data, and results of genetic analysis were evaluated.

Results: A total of 224 patients were included, of whom 101 (45%) were female, and the mean age at diagnosis was 9.4±4.1 years. Gene variant distribution was: 146 (65%) GCK; 43 (19%) ; 8 (3.6%) , 8 (3.6%) and 7 (3.1%) . The remaining 12 variants were: (n=1), (n=3), (n=1), (n=3), (n= 3) and (n=1). Of the cases, 197 (87.9%) were diagnosed with incidental hyperglycemia, 16 with ketosis (7%) and 7 (3%) with diabetic ketoacidosis (DKA), while 30% presented with classical symptoms of diabetes. Two-hundred (89%) had a family history of diabetes. Anti-GAD antibody was detected in 13 cases, anti-islet antibody in eight and anti-insulin antibody in four. Obesity was present in 16. Distribution of therapy was: 158 (71%) diet only; 23 (11%) intensive insulin treatment; 17 (7.6%) sulfonylureas; 10 (4.5%) metformin; and 6 (2.7%) insulin and oral anti-diabetic treatment.

Conclusion: This was the largest genetically diagnosed series from Turkey. The most common gene variants were GCK and HNF1A with much lower proportions for other MODY types. Hyperglycemia was the most common presenting symptom while 11% of patients had diabetes-associated autoantibodies and 7% were obese. The majority of patients received dietary management only.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11590772PMC
http://dx.doi.org/10.4274/jcrpe.galenos.2024.2023-10-16DOI Listing

Publication Analysis

Top Keywords

clinical laboratory
12
laboratory characteristics
8
mody cases
8
phenotype-genotype relationship
8
genetically diagnosed
8
n=1 n=3
8
n=3 n=1
8
mody
5
cases
5
characteristics mody
4

Similar Publications

Systemic Delivery of an mRNA-Encoding, Tumor-Activated Interleukin-12 Lock to Eliminate Tumors and Avoid Immune-Related Adverse Events.

Nano Lett

September 2025

Molecular Science and Biomedicine Laboratory (MBL), State Key Laboratory of Chemo/Biosensing and Chemometrics, College of Chemistry and Chemical Engineering, College of Biology, Aptamer Engineering Center of Hunan Province, Hunan University, Changsha 410082, China.

Interleukin-12 (IL-12) is a robust proinflammatory cytokine that activates immune cells, such as T cells and natural killer cells, to induce antitumor immunity. However, the clinical application of recombinant IL-12 has been limited by systemic immune-related adverse events (irAEs) and rapid degradation. To address these challenges, we employed mRNA technology to encode a tumor-activated IL-12 "lock" fusion protein that offers both therapeutic efficacy and systemic safety.

View Article and Find Full Text PDF

Recent Advances in Gene Therapy for Hemophilia.

Clin Appl Thromb Hemost

September 2025

Pediatric Hematology Laboratory, Division of Hematology/Oncology, Department of Pediatrics, The Seventh Affiliated Hospital of Sun Yat-Sen University, Shenzhen, Guangdong, China.

Hemophilia, an X-linked monogenic disorder, arises from mutations in the or genes, which encode clotting factor VIII (FVIII) or clotting factor IX (FIX), respectively. As a prominent hereditary coagulation disorder, hemophilia is clinically manifested by spontaneous hemorrhagic episodes. Severe cases may progress to complications such as stroke and arthropathy, significantly compromising patients' quality of life.

View Article and Find Full Text PDF

This commentary reflects three decades of interaction between the Cuban neuroinformatics tradition and the statistical parametric mapping (SPM) framework. From the early development of neurometrics in Cuba to global initiatives like the Global Brain Consortium, our trajectory has paralleled and intersected with that of SPM. We highlight shared commitments to generative modeling, Bayesian inference, and population-level brain mapping, as shaped through collaborations, workshops, and joint theoretical work with Karl Friston and his group.

View Article and Find Full Text PDF

SPM-30 years and beyond.

Cereb Cortex

August 2025

Functional Imaging Laboratory (FIL), Department of Imaging Neuroscience, University College London, 12 Queen Square, London WC1N 3AR, United Kingdom.

This paper marks the 30th anniversary of the Statistical Parametric Mapping (SPM) software and the journal Cerebral Cortex: two modest milestones that mark the inception of cognitive neuroscience. We take this opportunity to reflect on SPM, a generation after its introduction. Each of the authors of this paper-who represent a small selection of the many contributors to SPM-were asked to consider lessons learned, what has gone well, and where there is room for improvement in future development.

View Article and Find Full Text PDF